Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SB17 (Ustekinumab Biosimilar) vs Stelara in Plaque Psoriasis
NCT04967508Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of ustekinumab-ttwe in plaque psoriasis, sponsored by Samsung Bioepis. Started Jul 2021; status: completed.
02
Drugs
ustekinumab-ttwe
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04967508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967508.